Vir Biotechnology Financial Statements
NASDAQ: VIRHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Vir Biotechnology revenue and earnings
In fiscal 2025, Vir Biotechnology generated $68.6 million in revenue, down 7.6% from fiscal 2024, its first annual decline since 2024. Vir Biotechnology reported a net loss of $438.0 million, compared with a loss of $522.0 million a year earlier. Gross margin was 100.0% (up from 98.9%) and operating margin -699.2%.
Diluted earnings per share came in at -$3.16. Over the last 5 fiscal years, VIR's revenue has grown at a -2.1% compound annual rate (a contraction).
Summary generated from market data by MetaCap's automated system. Methodology
Vir Biotechnology income statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 68.56M | 74.20M | 86.18M | 1.62B | 1.10B | 76.37M | 8.09M | 10.67M | 2.71M |
| Revenue growth (YoY) | -7.61% | -13.90% | -94.67% | +47.51% | +1334.39% | +843.86% | -24.16% | +293.94% | — |
| Cost of Revenue | 26.00K | 845.00K | 2.77M | 146.32M | 65.86M | 0 | 0 | — | — |
| Gross Profit | 68.53M | 73.36M | 83.42M | 1.47B | 1.03B | 76.37M | 8.09M | — | — |
| Operating Expenses | 547.86M | 660.52M | 767.72M | 636.41M | 608.80M | 373.35M | 186.07M | 129.36M | 84.20M |
| Research & Development | 455.97M | 506.50M | 579.72M | 474.65M | 448.01M | 302.41M | 148.47M | 100.23M | 62.51M |
| Selling, General & Admin | 92.07M | 119.03M | 174.44M | 161.76M | 160.79M | 70.94M | 37.60M | — | — |
| Operating Income | -479.33M | -587.16M | -684.30M | 833.07M | 420.75M | -296.98M | -177.98M | -118.69M | -81.50M |
| Other Income (Expense) | 41.56M | 64.06M | 56.11M | -78.79M | 129.05M | -1.63M | -3.45M | 2.33M | 721.00K |
| Pretax Income | -437.77M | -523.11M | -628.19M | 754.28M | 549.80M | -298.61M | -174.53M | -116.36M | -80.78M |
| Income Tax | 217.00K | -1.15M | -13.08M | 238.44M | 21.22M | 54.00K | 154.00K | -480.00K | -10.92M |
| Net Income | -437.99M | -521.96M | -615.06M | 515.84M | 528.58M | -298.67M | -174.68M | -115.88M | -69.85M |
| Net Income growth (YoY) | — | — | -219.24% | -2.41% | — | — | — | — | — |
| EPS (Basic) | -3.16 | -3.83 | -4.59 | 3.89 | 4.07 | -2.51 | -5.76 | -15.12 | -32.45 |
| EPS (Diluted) | -3.16 | -3.83 | -4.59 | 3.83 | 3.96 | -2.51 | -5.76 | -15.12 | -32.45 |
| Shares Outstanding (Basic) | 138.52M | 136.25M | 134.13M | 132.61M | 129.88M | 119.16M | 30.35M | 7.67M | 2.15M |
| Shares Outstanding (Diluted) | 138.52M | 136.25M | 134.13M | 134.81M | 133.44M | 119.16M | 30.35M | 7.67M | 2.15M |
| EBITDA | -467.65M | -572.61M | -664.85M | 839.85M | 426.03M | -292.58M | -174.69M | -117.07M | -81.24M |
| Gross Margin | 99.96% | 98.86% | 96.79% | 90.94% | 93.99% | 100.00% | 100.00% | — | — |
| Operating Margin | -699.18% | -791.27% | -794.04% | 51.56% | 38.41% | -388.88% | -2199.72% | -1112.60% | -3009.49% |
| Net Margin | -638.87% | -703.40% | -713.69% | 31.92% | 48.25% | -391.09% | -2158.98% | -1086.28% | -2579.47% |
This table shows 9 annual periods of Vir Biotechnology's income statement, from FY 2025 back to FY 2017, across 19 line items including revenue, cost of revenue, gross profit. Values in USD; B = billions, M = millions. Fiscal periods follow VIR's reporting calendar. What is a income statement?